Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.40 USD
Change Today +0.23 / 2.06%
Volume 8.1K
NKTR On Other Exchanges
As of 9:30 AM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

455 Mission Bay Boulevard South

San Francisco, CA 94158

United States

Phone: 415-482-5300

Fax: 415-339-5300

Nektar Therapeutics, a biopharmaceutical company, develops a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The company’s proprietary pipeline comprises drug candidates across various therapeutic areas, including oncology, pain, anti-infectives and immunology. The company’s research and development activities involve small molecule drugs, peptides and other biologic drug candidates. The company creates drug candidates by using its proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of pharmacophores to create new molecular entities. In 2014, the company achieved the first approval of one of its proprietary drug candidates, MOVANTIK, under a global license agreement with AstraZeneca AB (AstraZeneca). MOVANTIK is an oral peripherally-acting mu-opioid antagonist (PAMORA), approved in both the United States (U.S.) and Europe for the treatment of opioid-induced constipation (OIC), a common side effect caused by chronic administration of prescription opioid pain medicines. MOVANTIK was developed using the company’s oral small molecule polymer conjugate technology and it advanced this drug through the completion of Phase 2 clinical studies prior to licensing it to AstraZeneca. The company is developing etirinotecan pegol (also known as NKTR-102), a next generation topoisomerase I (topo I) inhibitor which was designed using its PEGylation technology. Etirinotecan pegol is being evaluated as a single-agent therapy (145 mg/m2 every 21 days) in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer. NKTR-181 is an orally-available mu-opioid analgesic drug candidate for chronic pain conditions. In 2013, the company announced results from a human abuse liability study that demonstrated that NKTR-181 had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested. NKTR-214 is an engineered immunostimulatory cytokine and is being developed for the treatment of solid tumors. NKTR-214 is engineered to selectively activate IL-2 receptors on the surface of cytotoxic T cells that kill tumor cells while imparting substantially reduced affinity for IL-2 receptors present on the regulatory T cells that would otherwise dampen the immune response to tumors. The product candidate is in Investigational New Drug application-enabling studies. In 2014, the company had an end-of-Phase 2 meeting for NKTR-181 with United States Food and Drug Administration (FDA), which included discussions of certain considerations for the Phase 3 clinical study program. The company also has additional proprietary preclinical and clinical drug candidates in research and development. It has an ongoing Phase 1 clinical development program for NKTR-171, a new sodium channel blocker being developed as a potential oral therapy for the treatment of peripheral neuropathic pain. The company is also advancing various other drug candidates in preclinical development in the areas of cancer immunotherapy, pain and other therapeutic indications. NKTR-171 is a new molecular entity that is designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system. In January 2015, a multiple-ascending dose Phase 1 clinical study was initiated to assess its pharmacokinetics, tolerability, and safety of NKTR-171. Agreements The company has collaboration with Baxter Healthcare SA and Baxter Healthcare Corporation (Baxter), to identify and develop PEGylated drug candidates with the objective of providing new long-acting therapies for hemophilia patients. Under the terms of this collaboration, the company is providing its PEGylation technology and expertise and Baxter is responsible for all clinical development. The first drug candidate in this collaboration is BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for h


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $11.40 USD +0.23

NKTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $20.00 USD +0.18
Emergent BioSolutions Inc $29.00 USD +0.14
Ironwood Pharmaceuticals Inc $11.01 USD -0.06
Sucampo Pharmaceuticals Inc $21.48 USD 0.00
Theravance Inc $8.56 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NKTR Industry Range
Price/Earnings 100.0x
Price/Sales 5.2x
Price/Book 42.1x
Price/Cash Flow 243.0x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at